顺铂联合紫杉醇脂质体治疗晚期肺鳞癌的临床观察.doc

顺铂联合紫杉醇脂质体治疗晚期肺鳞癌的临床观察.doc顺铂联合紫杉醇脂质体治疗晚期肺鳞癌的临床观察【摘要】目的: 观察评价顺铂联合紫杉醇脂质体一线治疗晚期肺鳞癌的疗效和毒性反应。方法: 选取 2011 年4月-2014 年8 月经病理组织学确诊的 84例Ⅲ~Ⅳ期肺鳞癌患者,采用顺铂联合紫杉醇脂质体方案进行一线治疗,化疗至少 2 个周期后分别按照 RECIST 和 CTC 标准评价疗效和不良反应。结果: 84 例患者共完成 168 个周期化疗, 均可评价疗效和毒性反应,最终完全缓解 6 例,部分缓解 32 例,有效率为 % ( 38/84 )。主要毒副反应为白细胞减少及血小板减少, 但均可耐受。化疗后, % 患者的 KPS 评分增加≥10分, % 患者体重增加2kg 以上, % 患者症状改善。结论: 顺铂联合紫杉醇脂质体一线治疗晚期肺鳞癌具有较好的疗效,毒副反应轻,患者易于耐受,值得临床推广应用。【关键词】非小细胞肺癌; 紫杉醇脂质体; 顺铂; binational Therapeutic Efficacy of Cisplatin and Liposomal Paclitaxel in the First Line Treatment of Advanced Lung Squamous Cell Cancer/WU Yun-li , HUANG Jing , WANG Wei-wei , et al.//Medical Innovation of China , 2016 , 13( 04): 131-133 【 Abstract 】 Objective : To observe and binational therapeutic efficacy and side effects of cisplatin and liposomal paclitaxel in the first line treatment of advanced lung squamous cell cancer patients. Method : Eighty-four advanced ( stage :Ⅲ-Ⅳ) lung squamous cell cancer patients were enrolled and pathological diagnosis were all verified. After 2 cycles of cisplatin and liposomal binational treatment , we evaluated efficacy and side effects based on RECIST and CTC . Result : Eighty-four patients plished 168 cycles treatment in total and that satisfied statistically analysis. Response rate was % ( 38/84 ), which contained 6 cases of CR, 32 cases of PR. The main side effects was leukocytopenia and thrombocytopenia.